ALNY – Alnylam Pharmaceuticals, Inc.

Stock Forums Stocks Forum Nasdaq Stocks ALNY – Alnylam Pharmaceuticals, Inc.

This topic contains 3 replies, has 1 voice, and was last updated by 2 months, 2 weeks ago.

  • Creator
    Topic
  • #166351

    Stocks News Feed
    @admin

    ALNY – Alnylam Pharmaceuticals, Inc. – Stock Forum

Viewing 3 replies - 1 through 3 (of 3 total)
  • Author
    Replies
  • #265809
    Stocks News Feed
    @admin

    Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

    Alnylam Pharmaceuticals, Inc. (Nasdaq: $ALNY), the leading RNAi therapeutics company, announced today positive complete results from the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP). The clinical data are being presented in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ being held April 10-14 in Vienna, Austria.

    The full ENVISION results demonstrated a 74 percent mean and 90 percent median reduction in the primary endpoint measure of annualized rate of composite attacks in patients on givosiran relative to placebo during the six-month double-blind period. In addition, givosiran achieved statistically significant positive results for five of nine secondary endpoints, with an overall safety and tolerability profile that the Company believes is encouraging, especially in this high unmet need disease. Adverse events (AEs) were reported in 89.6 percent of givosiran patients and 80.4 percent of placebo patients; serious adverse events (SAEs) were reported in 20.8 percent of givosiran patients and 8.7 percent of placebo patients. Ninety-three of 94 patients, or 99 percent, enrolled in the open-label extension (OLE) period of the study. Based on the ENVISION results, the Company plans to complete its rolling submission of a New Drug Application (NDA) and file a Marketing Authorisation Application (MAA) in mid-2019.

    http://35.232.140.26/businesswire/alnylam-presents-positive-complete-results-from-envision-phase-3-study-of-givosiran-an-investigational-rnai-therapeutic-for-the-treatment-of-acute-hepatic-porphyria/

    #204538
    Stocks News Feed
    @admin

    Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings
    http://35.232.140.26/businesswire/alnylam-submits-cta-application-for-aln-agt-an-investigational-rnai-therapeutic-for-the-treatment-of-hypertension-in-high-unmet-need-settings/

    #193959
    Stocks News Feed
    @admin

    Alnylam Pharmaceuticals, Inc. ALNY announced that its Phase 3 trial of givosiran, for the treatment of acute hepatic porphyria (AHP), met its primary endpoint of reduction in the annualized rate of composite porphyria attacks relative to placebo (p less than 0.00000001). However, investors sold off noting safety concerns, with serious adverse events previously reported in 10/48 (20.8 percent) of givosiran patients compared with 4/46 (8.7 percent) of placebo patients.
    http://35.232.140.26/businesswire/alnylam-reports-positive-topline-results-from-envision-phase-3-study-of-givosiran-in-acute-hepatic-porphyria/

Viewing 3 replies - 1 through 3 (of 3 total)

You must be logged in to reply to this topic Login Register




Done Reading? You might also find these links useful:
Stock Market News | Stock Forums | Stock Market Products